期刊
AGING-US
卷 13, 期 19, 页码 22963-22984出版社
IMPACT JOURNALS LLC
关键词
pancreatic carcinoma; bioinformatics analysis; biomarkers; LAMC2; RUNX2
资金
- Natural Science Foundation Youth Fund Project of China [81902803]
- Natural Science Foundation of Zhejiang Province [LQ21H160043]
- Basic Scientific Research Project of Wenzhou [Y2020208]
The study identified RUNX2 and LAMC2 as promising targets for early diagnosis and therapy of pancreatic carcinoma, based on integrative analysis of multiple datasets.
Pancreatic carcinoma (PC) is a severe disease associated with high mortality. Although strategies for cancer therapy have made great progress, outcomes of pancreatic carcinoma patients remain extremely poor. Therefore, it is urgent to find novel biomarkers and therapeutic targets. To identify biomarkers for early diagnosis and therapy, three mRNA microarray datasets and two miRNA datasets were selected, and combinative analysis was performed by GEO2R. Functional and pathway enrichment analysis were performed using DAVID database. MiRTarBase, miRWalk and Diana Tools were used to get key genes. TCGA, HPA and western blotting were used to verify diagnostic and prognostic value of key genes. By integrating mRNA and miRNA expression profiles, we identified 114 differentially expressed genes and 114 differentially expressed miRNAs, respectively. Then, three overlapping key genes, RUNX2, LAMC2 and FBXO32, were found. Their protein levels in pancreatic tissue from PC patients and normal people were analyzed by immunohistochemical staining and western blotting. RUNX2 showed a potential property to identify PC. Aberrant over-expression of LAMC2 was associated with poor prognosis of PC patients, tumor status and subtypes. In summary, our current study identified that RUNX2 and LAMC2 may be promising targets for early diagnosis and therapy of PC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据